Halozyme治疗技术公司在面临拒绝后撤回21亿美元Evotec SE收购投标。 Halozyme Therapeutics withdraws $2.1 billion Evotec SE acquisition bid after facing rejection.

在德国公司对讨论无兴趣并希望保持独立之后,Halozyme治疗公司撤回了21亿美元的收购Evotec SE的提议。 Halozyme Therapeutics has withdrawn its $2.1 billion proposal to acquire Evotec SE after the German company showed no interest in discussions and wished to remain independent. Halozyme的股份上升了6.21%,而Evotec的股份在宣布后下降了18.8%。 Halozyme's shares rose by 6.21%, while Evotec's fell by 18.8% following the announcement. Halozyme还重申其强劲的商业前景,预测2024年的收入在9.7亿至10.2亿美元之间。 Halozyme also reaffirmed its strong business outlook, forecasting 2024 revenue between $970 million and $1.02 billion.